细胞因子在类风湿性关节炎和骨破坏中的作用
摘要
形和功能丧失。本文综述了 IL-6、TNF-α以及基质金属蛋白酶（MMPs）在RA病理进程中的作用，并探讨了抗炎
细胞因子在控制炎症中的重要性。IL-6和TNF-α作为关键的促炎性细胞因子，显著促进破骨细胞的活化，加剧了
骨吸收和关节损伤，而MMPs则通过降解细胞外基质加速了软骨和骨组织的破坏。相反，抗炎性细胞因子如 IL-10、
IL-4和TGF-β在RA中的作用相对较弱，但对于调节免疫反应和抑制过度的炎症过程至关重要。本文进一步指出，
靶向抑制促炎因子的表达并增强抗炎因子的作用，可能为RA患者提供更加有效的治疗方案。未来研究应着重于平衡
促炎和抗炎因子的作用，以改善RA的治疗效果。
关键词
全文:
PDF参考
[ 1 ] F I R E S T E I N G S , M C I N N E S I B .
Immunopathogenesis of Rheumatoid Arthritis [J]. Immunity,
2017, 46(2): 183-96.
[2]张明媚，魏萌.炎症信号通路的DNA甲基化在类
风湿关节炎发病机制中的研究进展 %J 中国免疫学杂志
[J].2022，38（12）：1535-8.
[3]MUELLER A L, PAYANDEH Z, MOHAMMADK
HANI N, etal. Recent Advances in Understanding the Pathogenesis
of Rheumatoid Arthritis: New Treatment Strategies [J]. Cells,
2021, 10(11).
[4]ITOH Y. Metalloproteinases in Rheumatoid Arthritis:
Potential Therapeutic Targets to Improve Current Therapies
[J]. Progress in molecular biology and translational science,
2017, 148: 327-38.
117
现代医学前沿 | 第2卷/第12期
Advances in Mordern Medical
[5]JONES S A, SCHELLER J, ROSE-JOHN S.
Therapeutic strategies for the clinical blockade of IL-6/gp130
signaling [J]. J Clin Invest, 2011, 121(9): 3375-83.
[6]MCINNES I B, SCHETT G. The pathogenesis
of rheumatoid arthritis [J]. The New England journal of
medicine, 2011, 365(23): 2205-19.
[7]GABAY C. Interleukin-6 and chronic inflammation
[J]. Arthritis Res Ther, 2006, 8 Suppl 2(Suppl 2): S3.
[8]WEITZMANN M N, PACIFICI R. Estrogen
deficiency and bone loss: an inflammatory tale [J]. J Clin
Invest, 2006, 116(5): 1186-94.
[9]TAMURA T, UDAGAWA N, TAKAHASHI N, et
al. Soluble interleukin-6 receptor triggers osteoclast formation
by interleukin 6 [J]. Proceedings of the National Academy
of Sciences of the United States of America, 1993, 90(24):
11924-8.
[10]EMERY P, KEYSTONE E, TONY H P, et al.
IL-6 receptor inhibition with tocilizumab improves treatment
outcomes in patients with rheumatoid arthritis refractory to
anti-tumour necrosis factor biologicals: results from a 24-
week multicentre randomised placebo-controlled trial [J].
Ann Rheum Dis, 2008, 67(11): 1516-23.
[11]TOBEIHA M, MOGHADASIAN M H, AMIN
N, et al. RANKL/RANK/OPG Pathway: A Mechanism
Involved in Exercise-Induced Bone Remodeling [J]. BioMed
research international, 2020, 2020: 6910312.
[12]TOMPKINS K A. The osteoimmunology of alveolar
bone loss [J]. Connect Tissue Res, 2016, 57(2): 69-90.
[13]KWAN TAT S, PADRINES M, THEOLEYRE
S, et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in
bone resorption pathophysiology [J]. Cytokine Growth Factor
Rev, 2004, 15(1): 49-60.
[14]SADOWSKI T, STEINMEYER J. Effects of
tetracyclines on the production of matrix metalloproteinases
and plasminogen activators as well as of their natural
inhibitors, tissue inhibitor of metalloproteinases-1 and
plasminogen activator inhibitor-1 [J]. Inflammation research :
official journal of the European Histamine Research Society [et
al], 2001, 50(3): 175-82.
[15]GENDRON C, KASHIWAGI M, LIM N H, et
al. Proteolytic activities of human ADAMTS-5: comparative
studies with ADAMTS-4 [J]. J Biol Chem, 2007, 282(25):
18294-306.
[16]BURRAGE P S, MIX K S, BRINCKERHOFF C
E. Matrix metalloproteinases: role in arthritis [J]. Frontiers in
bioscience : a journal and virtual library, 2006, 11: 529-43.
[17 ]MOORE K W, DE WAAL MALEFYT R,
COFFMAN R L, et al. Interleukin-10 and the interleukin-
10 receptor [J]. Annual review of immunology, 2001, 19:
683-765.
[18]FIORENTINO D F, ZLOTNIK A, VIEIRA P,
et al. IL-10 acts on the antigen-presenting cell to inhibit
cytokine production by Th1 cells [J]. The Journal of
Immunology, 1991, 146(10): 3444-51.
[19]SATTAR S, SHABBIR A, SHAHZAD M, et al.
Eichhornia crassipes Ameliorated Rheumatoid Arthritis by
Modulating Inflammatory Cytokines and Metalloproteinase
Enzymes in a Rat Model [J]. Medicina (Kaunas), 2023, 59(9
Refbacks
- 当前没有refback。
